Industry News

Dr. Reddys Laboratories Ltd is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The initiative launched last month (21 June) by Vivli, a non-profit clinical research data sharing organisation, will enable scientists from all over the world to access data on epidemiological, physical and genetic characteristics of organisms and their resistance to various antibiotics.

NIPER SAS Nagar has informed that the highest annual package offered to a student is Rs. 27.8 lakh. Many companies conducted campus interviews for the M.Pharm or Masters students of the batch 2020-22.

Dr Reddys Laboratories has settled patent litigation with Indivior Inc and Aquestive Therapeutics on a medication used to treat opioid dependence or addiction. A US Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties, the Hyderabad-based drug major said in a statement.

Novartis starts a new plant in Mumbai to make generic cancer drugs. It said that to reinforce our commitment to improving and extending people’s lives, Sandoz Technical Operations, a Novartis division, inaugurated its manufacturing plant for medicines and therapies at Kalwe in Mumbai today.

The plant, which marks a new chapter for Sandoz, will further strengthen the company’s operations in India to support growing healthcare needs globally.

Dr. Reddy's Laboratories Ltd.announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois, based Eton Pharmaceuticals, Inc.

U.S. FDA has issued Form 483 with six observations after an inspection at Glenmark Pharma's formulation manufacturing facility based out of Baddi, India between June 13, 2022 and June 22, 2022.

Harish Kuber, Company Secretary & Compliance Officer, Glenmark Pharma said, The Company is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

Inaugurating a two-day biotechnology start-up expo and launching a portal for biotech products at Pragati Maidan here on Thursday, Prime Minister Narendra Modi expressed confidence that India was on the verge of becoming part of the top 10 countries in biotechnology. “India's bio-economy has grown eight times in the last eight years. We have grown from 10 billion dollar to 80 billion dollar. India is not too far off from reaching the league of top-10 countries in Biotech's global ecosystem”, he said.